Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys in Chronic Myeloproliferative Diseases
NCT00452023Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2005
- Primary completion
- May 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of interferon alfa in essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), Atypical chronic myeloid leukemia (aCML), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2005; status: completed.
02
Drugs
interferon alfa
03
Conditions
essential thrombocythemia (ET)polycythemia vera (PV)myelofibrosis (MF)Atypical chronic myeloid leukemia (aCML)
Beyond the preview
Go deeper on NCT00452023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00452023.